Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines

Oncology Research

Volumn 9, Issue 3, 1997, Pages 139-147

  McGuire, John J ^a   Magee, Kathryn J ^a   Russell, Cynthia A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

AG331; BW1843U89; Head and neck cancer; Thymidylate synthase; ZD1694

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ENZYME INHIBITOR; FOLINIC ACID; GROWTH INHIBITOR; METHOTREXATE; THYMIDYLATE SYNTHASE;

ARTICLE; CELL CULTURE; CELL DIVISION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; HEAD AND NECK TUMOR; HUMAN; LEUKEMIA;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GROWTH INHIBITORS; HEAD AND NECK NEOPLASMS; HUMANS; LEUCOVORIN; LEUKEMIA; METHOTREXATE; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0030633340     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Tobias, J. S. Current role of chemotherapy in head and neck cancer. Drugs 43:333-345; 1992.
2. McGuire, J. J.; Sobrero, A. F.; Hynes, J. B.; Bertino, J. R. Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells. Cancer Res. 47:5975-5981; 1987.
3. Bisson, L. F.; Thorner, J. Thymidylate synthetase from Saccharomyces cerevisiae. Purification and enzymic properties. J. Biol. Chem. 256:12456-12462; 1981.
4. Scanlon, K. J.; Newman, E. M.; Lu, Y.; Priest, D. G. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sei. USA 83:8923-8925; 1986.
5. Jackman, A. L.; Jones, T. R.; Calvert, A. H. Thymidylate synthetase inhibitors: Experimental and clinical aspects. In: Muggia, F. M.; ed. Experimental and clinical progress in cancer chemotherapy. Boston: Martinus Nijhoff; 1985:155-210.
6. Jackman, A. L.; Calvert, A. H. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol. 6:871-881; 1995.
7. Marsham, P. R.; Hughes, L. R.; Jackman, A. L.; Hayter, A. J.; Oldfield, J.; Wardleworth, J. M.; Bishop, J. A. M.; O'Connor, B. M.; Calvert, A. H. Quinazoline antifolate thymidylate synthase inhibitors: Heterocyclic benzoyl ring modifications. J. Med. Chem. 34:1594-1605; 1991.
8. Duch, D.; Banks, S.; Dev, I. K.; Dickerson, S. H.; Ferone, R.; Heath, L. S.; Humphreys, J.; Knick, V.; Pendergast, W.; Singer, S.; Smith, G. K.; Waters, K.; Wilson, H. R. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res. 53: 810-818; 1993.
9. Webber, S.; Shetty, B.; Johnston, A.; Welsh, K.; Varney, M.; Deal, J.; Morse, C.; Soda, K. In vitro properties and antitumor activity of AG-331, a novel lipophilic thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res. 33:413; 1992.
10. Jackman, A. L.; Taylor, G. A.; Gibson, W.; Kimbell, R.; Brown, M.; Calvert, A. H.; Judson, I. R.; Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and i/i vivo: A new agent for clinical study. Cancer Res. 51: 5579-5586;1991.
11. Blakley, R. L., ed. The biochemistry of folic acid and related pteridines. Amsterdam: Elsevier North-Holland; 1969:92-94.
12. McGuire, J. J.; Bergoltz, V. V.; Heitzman, K. J.; Haue, W. H.; Russell, C. A.; Bolanowska, W. E.; Kotake, Y.; Haneda, T.; Nomura, H. Novel 6,5-fused-ring heterocyclic antifolates: Biochemical and biological characterization. Cancer Res. 54: 2673-2679; 1994.
13. Wilkinson, R. F. The effect of charcoal/dextran treatment on select serum components. Art Sei. Tissue Culture 12:1-10; 1994.
14. Foley, G. F.; Lazarus, H.; Farber, S.; Uzman, B. G.; Boone, B. A.; McCarthy, R. E. Continuous culture of lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18:522-529; 1965.
15. Mini, E.; Srimatkandada, S.; Medina, W. D.; Moroson, B. A.; Carman, M. D.; Bertino, J. R. Molecular and karyological analysis of methotrexate-resistant and -sensitive human leukemic CCRF-CEM cells. Cancer Res. 45:317-325; 1985.
16. Rosowsky, A.; Lazarus, H.; Yuan, G. C.; Beltz, W. R.; Mangini, L.; Abelson, H. T.; Modest, E. J.; Frei, E., III. Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts. Biochem. Pharmacol. 29:648-652; 1980.
17. McCloskey, D. E.; McGuire, J. J.; Russell, C. A.; Rowan, B. G.; Bertino, J. R.; Pizzorno, G.; Mini, E. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J. Biol. Chem. 266:6181-6187; 1991.
18. Pizzorno, G.; Chang, Y.-M.; McGuire, J. J.; Bertino, J. R. Inherent resistance of human squamous cell lines to methotrexate as a result of decreased polyglutamylation of this drug. Cancer Res. 49:5275-5280; 1989.
19. McGuire, J. J.; Heitzman, K. J.; Haile, W. H.; Russell, C. A.; McCloskey, D. E.; Piper, J. R. Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexateresistant CCRF-CEM human leukemia sublines. Leukemia 7: 1996-2003; 1993.
20. McGuire, J. J.; Russell, C. A.; Bolanowska, W. E.; Freitag, C. M.; Jones, C. S.; Kaiman, T. I. Biochemical and growth inhibition studies of methotrexate and aminopterin analogues containing a tetrazole ring in place of the 7-carboxyl group. Cancer Res. 50:1726-1731; 1990.
21. Bertino, J. R. Rescue techniques in cancer chemotherapy: Use of leucovorin and other rescue agents after methotrexate treatment. Semin. Oncol. 4:203-216; 1977.
22. O'Connor, B. M.; Webber, S.; Jackson, R. C.; Galivan, J.; Rhee, M. S. Biological activity of a novel rationally designed lipophilic thymidylate synthase inhibitor. Cancer Chemother. Pharmacol. 34:225-229; 1994.
23. Yin, M. B.; Guimaraes, M. A.; Zhang, Z. G.; Arredondo, M. A.; Rustum, Y. Time dependence of DNA lesions and growth inhibition by ICI D 1694, a new quinazoline antifolate thymidylate synthase inhibitor. Cancer Res. 52:5900-5905; 1992.
24. Wilson, H. R.; Heath, L. S.; Knick, V. C.; Koszalla, G. W.; Ferone, R. In vivo antitumor activity of 1843U89, a new antifolate thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res. 33:407; 1992.
25. Banks, S. D.; Waters, K. A.; Barre, L. L.; Smith, G. K. Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor, 1843U89, at physiological thymidine concentrations. Proc. Am. Assoc. Cancer Res. 33: 407-407; 1992.
26. Jackman, A. L.; Kelland, L. R.; Kimbell, R.; Brown, M.; Gibson, W.; Aherne, G. W.; Hardcastle, A.; Boyle, F. T. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br. J. Cancer 71:914-924; 1995.